This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conrad, D A
Right arrow Articles by Marks, M I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conrad, D A
Right arrow Articles by Marks, M I

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1985 July; 28(1): 58-63

In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.

D A Conrad, R K Scribner, A H Weber and M I Marks

ABSTRACT

The antibacterial activity of BMY-28142, a new aminothiazole cephalosporin, was measured by standardized broth microdilution and agar dilution methods against 450 gram-positive and gram-negative bacteria isolated from pediatric infections, including acute pulmonary exacerbations of cystic fibrosis. BMY-28142 activity was compared with that of aminoglycosides, beta-lactams, chloramphenicol, trimethoprim-sulfamethoxazole, vancomycin, and clindamycin. The activity of BMY-28142 in combination with other antimicrobial agents against Pseudomonas aeruginosa was also determined. Furthermore, the effects of inoculum and pH on BMY-28142 activity were evaluated. BMY-21842 was active against most of the gram-positive and gram-negative isolates, with the exception of methicillin-resistant Staphylococcus aureus and Pseudomonas cepacia. The combination of BMY-28142 with tobramycin was often synergistic, and combinations of BMY-28142 with either polymyxin B or imipenem were usually antagonistic. BMY-28142 antibacterial activity could be adversely affected at extremes of medium pH and by high inoculum densities.

Antimicrob Agents Chemother. 1985 July; 28(1): 58-63




This article has been cited by other articles:

  • Lister, P. D., Sanders, W. E. Jr., Sanders, C. C. (1998). Cefepime-Aztreonam: a Unique Double beta -Lactam Combination for Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 42: 1610-1619 [Abstract] [Full Text]  
  • Arguedas, A. G., Stutman, H. R., Zaleska, M., Knupp, C. A., Marks, M. I., Nussbaum, E. (1992). Cefepime: Pharmacokinetics and Clinical Response in Patients With Cystic Fibrosis. Arch Pediatr Adolesc Med 146: 797-802 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»